RenovoRx, Inc. (RNXT) Q3 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good afternoon. I will be your conference call operator today. Please note that today's call is being recorded and all participants other than management are in listen-only mode. There will be a Q&A session following the management's presentation. I will now turn the call over to Walter Pinto, Managing Director of KCSA Strategic Communications. Please go ahead. Thank you. Thank you, Operator. Good afternoon, everyone, and welcome to Renovo Rx's third quarter 2025 conference call. I'm joined today by members of our leadership team, Dr. Ramtan Agha, Chairman, Founder, and Chief Medical Officer, Sean Begay, Chief Executive Officer, Lisa Gentry, Chief Clinical Officer, and Ronald Kozak, VP, Controller, and Principal Accounting Officer. Before we begin, I'd like to remind everyone that statements made during today's call contain or may contain forward-looking statements. covered by the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and applicable federal securities laws. These statements, including statements regarding Renovo's clinical and commercial plans, strategies, and estimates of performance, are based on management's current plans and assumptions, and actual results may differ materially. Please refer to our filings with the SEC, including our Form 10-Q for the third quarter of 2025 and our most recent Form 10-K, for a detailed discussion of the risks and uncertainties facing Renovo Rx. With that, I'd like to turn the call over to our chairman, founder, and chief medical officer, Dr. Ramtan Agha. Thank you, Walter, and good afternoon, everyone. This quarter marks another important step forward in Renovo Rx's 14-year journey transforming a bold concept into a new therapeutic option that is now reaching patients across the country. Ou...